1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
The nucleoside reverse transcriptase inhibitor (NRTI) market is experiencing dynamic changes, spurred by portfolio evolution, regulatory shifts, and new delivery strategies. Senior leaders must navigate both increasing complexity and opportunity across therapeutic development, supply chains, and commercialization.
Market Snapshot: NRTIs at a Strategic Crossroads
NRTIs serve as a cornerstone of antiretroviral therapy, providing durable viral suppression and supporting improved lifetime outcomes for people living with HIV. The market is shaped by medicinal chemistry advancements that optimize efficacy, tolerability, and resistance, alongside strong market demand for innovative therapeutics and adaptive formulations.
Scope & Segmentation of the NRTI Market
- Molecules: Abacavir, Didanosine, Emtricitabine, Lamivudine, Stavudine, Zidovudine
- Dosage Forms: Capsule, Injection, Solution, Tablet
- Routes of Administration: Oral, Parenteral
- Therapy Types: Combination Therapy (Dual Therapy, Triple Therapy), Monotherapy
- Distribution Channels: Hospital Pharmacy, Online Pharmacy (Direct Distribution, E Pharmacy), Retail Pharmacy (Chain Pharmacy, Independent Pharmacy)
- Patient Demographics: Adult, Pediatric
- Regional Scope: Americas (United States: California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada; Mexico; Brazil; Argentina), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
- Key Companies: Gilead Sciences, Inc., ViiV Healthcare Limited, Viatris Inc., Teva Pharmaceutical Industries Limited, Cipla Limited, Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Limited, Lupin Limited, Hetero Drugs Limited, Zydus Lifesciences Limited
Key Takeaways for Senior Decision-Makers
- Molecular innovation continues to redefine NRTI formulations, enabling optimized regimens targeting resistance, tolerability, and simplified dosing for diverse patient groups.
- Patent expirations accelerate the entry of generics, reshaping pricing structures and compelling original manufacturers to differentiate through delivery technologies and safety improvements.
- Expedited regulatory approvals have fast-tracked the pathway for fixed-dose combinations, promoting single-tablet regimens and enhanced adherence outcomes.
- Real-world clinical practice increasingly integrates patient engagement tools and digital adherence platforms, broadening the market’s push for holistic health outcomes.
- Geographic variations impact product adoption, with public health initiatives, pricing models, and procurement strategies differing widely by region, shaping competitive approaches.
- Strategic alliances, licensing agreements, and co-development pacts drive product innovations, pipeline progression, and expanded market presence for lead enterprises.
Tariff Impact: 2025 and Supply Chain Adaptations
The 2025 United States tariff increases introduced new cost considerations for NRTI producers and distributors. Companies have responded by diversifying supplier relationships, exploring regional production, and adopting blended sourcing models to guard against disruption. Custom bond warehousing and tariff-adjustment clauses in pricing negotiations help stabilize margins and support continuous patient access during market volatility.
Research Methodology & Data Sources
This report is grounded in secondary research across peer-reviewed literature, regulatory databases, and industry publications, combined with primary interviews involving infectious disease experts, payers, and manufacturing executives. Data triangulation and expert validation processes ensure the findings are reliable and cover all key dimensions of the NRTI market.
Why This Report Matters
- Enables executives to anticipate market disruptions and align strategies with emerging regulatory and supply dynamics.
- Informs commercialization decisions by highlighting shifting demand drivers, regional variations, and stakeholder engagement best practices.
- Provides clear segmentation, offering actionable insights for product development, procurement optimization, and competitive differentiation.
Conclusion
Strategic action on innovation, operational resilience, and market adaptation is crucial as the NRTI market evolves. Leaders equipped with these insights will be positioned to capture value and support patient outcomes in a changing therapeutic landscape.
This product will be delivered within 1-3 business days.
Table of Contents
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Increasing adoption of tenofovir alafenamide prodrugs in new fixed dose HIV therapies
5.2. Expansion of long acting injectable NRTI formulations to improve patient adherence rates
5.3. Impact of generic lamivudine and zidovudine entry on NRTI pricing and accessibility
5.4. Regulatory fast track approvals for novel NRTI analogues targeting multidrug resistant HIV strains
5.5. Integration of NRTI based therapies into combinational regimens for hepatitis B coinfection management
5.6. Rising demand for pediatric NRTI formulations with weight based dosing in emerging markets
5.7. Advancements in antiviral safety profiles reduce mitochondrial toxicity associated with NRTI therapy
5.2. Expansion of long acting injectable NRTI formulations to improve patient adherence rates
5.3. Impact of generic lamivudine and zidovudine entry on NRTI pricing and accessibility
5.4. Regulatory fast track approvals for novel NRTI analogues targeting multidrug resistant HIV strains
5.5. Integration of NRTI based therapies into combinational regimens for hepatitis B coinfection management
5.6. Rising demand for pediatric NRTI formulations with weight based dosing in emerging markets
5.7. Advancements in antiviral safety profiles reduce mitochondrial toxicity associated with NRTI therapy
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
6.2. PESTLE Analysis
8. Nucleoside Reverse Transcriptase Inhibitors Market, by Molecule
8.1. Introduction
8.2. Abacavir
8.3. Didanosine
8.4. Emtricitabine
8.5. Lamivudine
8.6. Stavudine
8.7. Zidovudine
8.2. Abacavir
8.3. Didanosine
8.4. Emtricitabine
8.5. Lamivudine
8.6. Stavudine
8.7. Zidovudine
9. Nucleoside Reverse Transcriptase Inhibitors Market, by Dosage Form
9.1. Introduction
9.2. Capsule
9.3. Injection
9.4. Solution
9.5. Tablet
9.2. Capsule
9.3. Injection
9.4. Solution
9.5. Tablet
10. Nucleoside Reverse Transcriptase Inhibitors Market, by Route Of Administration
10.1. Introduction
10.2. Oral
10.3. Parenteral
10.2. Oral
10.3. Parenteral
11. Nucleoside Reverse Transcriptase Inhibitors Market, by Therapy Type
11.1. Introduction
11.2. Combination Therapy
11.2.1. Dual Therapy
11.2.2. Triple Therapy
11.3. Monotherapy
11.2. Combination Therapy
11.2.1. Dual Therapy
11.2.2. Triple Therapy
11.3. Monotherapy
12. Nucleoside Reverse Transcriptase Inhibitors Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.3.1. Direct Distribution
12.3.2. E Pharmacy
12.4. Retail Pharmacy
12.4.1. Chain Pharmacy
12.4.2. Independent Pharmacy
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.3.1. Direct Distribution
12.3.2. E Pharmacy
12.4. Retail Pharmacy
12.4.1. Chain Pharmacy
12.4.2. Independent Pharmacy
13. Nucleoside Reverse Transcriptase Inhibitors Market, by Patient Demographics
13.1. Introduction
13.2. Adult
13.3. Pediatric
13.2. Adult
13.3. Pediatric
14. Americas Nucleoside Reverse Transcriptase Inhibitors Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Nucleoside Reverse Transcriptase Inhibitors Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Nucleoside Reverse Transcriptase Inhibitors Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Gilead Sciences, Inc.
17.3.2. ViiV Healthcare Limited
17.3.3. Viatris Inc.
17.3.4. Teva Pharmaceutical Industries Limited
17.3.5. Cipla Limited
17.3.6. Aurobindo Pharma Limited
17.3.7. Dr. Reddy’s Laboratories Limited
17.3.8. Lupin Limited
17.3.9. Hetero Drugs Limited
17.3.10. Zydus Lifesciences Limited
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Gilead Sciences, Inc.
17.3.2. ViiV Healthcare Limited
17.3.3. Viatris Inc.
17.3.4. Teva Pharmaceutical Industries Limited
17.3.5. Cipla Limited
17.3.6. Aurobindo Pharma Limited
17.3.7. Dr. Reddy’s Laboratories Limited
17.3.8. Lupin Limited
17.3.9. Hetero Drugs Limited
17.3.10. Zydus Lifesciences Limited
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 8. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 16. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET: RESEARCHAI
FIGURE 28. NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET: RESEARCHSTATISTICS
FIGURE 29. NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET: RESEARCHCONTACTS
FIGURE 30. NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET: RESEARCHARTICLES
FIGURE 2. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 8. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 16. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET: RESEARCHAI
FIGURE 28. NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET: RESEARCHSTATISTICS
FIGURE 29. NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET: RESEARCHCONTACTS
FIGURE 30. NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ABACAVIR, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ABACAVIR, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DIDANOSINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DIDANOSINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY EMTRICITABINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY EMTRICITABINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY LAMIVUDINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY LAMIVUDINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY STAVUDINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY STAVUDINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ZIDOVUDINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ZIDOVUDINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY SOLUTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY SOLUTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DUAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DUAL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY TRIPLE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY TRIPLE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DIRECT DISTRIBUTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DIRECT DISTRIBUTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY E PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY E PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 117. CANADA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 118. CANADA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 119. CANADA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 120. CANADA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 121. CANADA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 122. CANADA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 123. CANADA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 124. CANADA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 125. CANADA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 126. CANADA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 127. CANADA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 128. CANADA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 129. CANADA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 130. CANADA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 131. CANADA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 132. CANADA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 133. CANADA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 134. CANADA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 135. MEXICO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 136. MEXICO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 137. MEXICO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 138. MEXICO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 139. MEXICO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 140. MEXICO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 141. MEXICO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 142. MEXICO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 143. MEXICO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 144. MEXICO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 145. MEXICO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 146. MEXICO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 147. MEXICO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 148. MEXICO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 149. MEXICO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 150. MEXICO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 151. MEXICO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 152. MEXICO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 153. BRAZIL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 154. BRAZIL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 155. BRAZIL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 156. BRAZIL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 171. ARGENTINA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 172. ARGENTINA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 173. ARGENTINA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 174. ARGENTINA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 175. ARGENTINA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 176. ARGENTINA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 177. ARGENTINA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 178. ARGENTINA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 183. ARGENTINA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 184. ARGENTINA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 185. ARGENTINA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 186. ARGENTINA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 187. ARGENTINA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 188. ARGENTINA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 210. UNITED KINGDOM NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 212. UNITED KINGDOM NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 214. UNITED KINGDOM NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 216. UNITED KINGDOM NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 218. UNITED KINGDOM NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 220. UNITED KINGDOM NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 222. UNITED KINGDOM NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 224. UNITED KINGDOM NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 226. UNITED KINGDOM NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 227. GERMANY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 228. GERMANY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 229. GERMANY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 230. GERMANY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 231. GERMANY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 232. GERMANY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 233. GERMANY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 234. GERMANY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 235. GERMANY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 236. GERMANY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 237. GERMANY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 238. GERMANY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 239. GERMANY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 240. GERMANY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 241. GERMANY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 242. GERMANY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 243. GERMANY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 244. GERMANY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 245. FRANCE NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 246. FRANCE NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 247. FRANCE NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 248. FRANCE NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 249. FRANCE NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 250. FRANCE NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 251. FRANCE NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 252. FRANCE NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 253. FRANCE NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 254. FRANCE NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 255. FRANCE NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 256. FRANCE NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 257. FRANCE NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 258. FRANCE NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 259. FRANCE NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 260. FRANCE NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 261. FRANCE NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 262. FRANCE NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 263. RUSSIA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 264. RUSSIA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 265. RUSSIA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 266. RUSSIA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 267. RUSSIA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUT
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ABACAVIR, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ABACAVIR, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DIDANOSINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DIDANOSINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY EMTRICITABINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY EMTRICITABINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY LAMIVUDINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY LAMIVUDINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY STAVUDINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY STAVUDINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ZIDOVUDINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ZIDOVUDINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY SOLUTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY SOLUTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DUAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DUAL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY TRIPLE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY TRIPLE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DIRECT DISTRIBUTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DIRECT DISTRIBUTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY E PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY E PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 117. CANADA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 118. CANADA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 119. CANADA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 120. CANADA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 121. CANADA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 122. CANADA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 123. CANADA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 124. CANADA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 125. CANADA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 126. CANADA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 127. CANADA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 128. CANADA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 129. CANADA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 130. CANADA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 131. CANADA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 132. CANADA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 133. CANADA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 134. CANADA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 135. MEXICO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 136. MEXICO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 137. MEXICO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 138. MEXICO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 139. MEXICO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 140. MEXICO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 141. MEXICO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 142. MEXICO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 143. MEXICO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 144. MEXICO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 145. MEXICO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 146. MEXICO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 147. MEXICO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 148. MEXICO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 149. MEXICO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 150. MEXICO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 151. MEXICO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 152. MEXICO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 153. BRAZIL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 154. BRAZIL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 155. BRAZIL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 156. BRAZIL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 171. ARGENTINA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 172. ARGENTINA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 173. ARGENTINA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 174. ARGENTINA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 175. ARGENTINA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 176. ARGENTINA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 177. ARGENTINA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 178. ARGENTINA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 183. ARGENTINA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 184. ARGENTINA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 185. ARGENTINA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 186. ARGENTINA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 187. ARGENTINA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 188. ARGENTINA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 210. UNITED KINGDOM NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 212. UNITED KINGDOM NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 214. UNITED KINGDOM NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 216. UNITED KINGDOM NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 218. UNITED KINGDOM NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 220. UNITED KINGDOM NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 222. UNITED KINGDOM NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 224. UNITED KINGDOM NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 226. UNITED KINGDOM NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 227. GERMANY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 228. GERMANY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 229. GERMANY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 230. GERMANY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 231. GERMANY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 232. GERMANY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 233. GERMANY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 234. GERMANY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 235. GERMANY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 236. GERMANY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 237. GERMANY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 238. GERMANY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 239. GERMANY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 240. GERMANY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 241. GERMANY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 242. GERMANY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 243. GERMANY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 244. GERMANY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 245. FRANCE NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 246. FRANCE NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 247. FRANCE NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 248. FRANCE NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 249. FRANCE NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 250. FRANCE NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 251. FRANCE NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 252. FRANCE NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 253. FRANCE NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 254. FRANCE NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 255. FRANCE NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 256. FRANCE NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 257. FRANCE NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 258. FRANCE NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 259. FRANCE NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 260. FRANCE NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 261. FRANCE NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 262. FRANCE NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 263. RUSSIA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 264. RUSSIA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 265. RUSSIA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 266. RUSSIA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 267. RUSSIA NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY ROUT
Samples
LOADING...
Companies Mentioned
The companies profiled in this Nucleoside Reverse Transcriptase Inhibitors market report include:- Gilead Sciences, Inc.
- ViiV Healthcare Limited
- Viatris Inc.
- Teva Pharmaceutical Industries Limited
- Cipla Limited
- Aurobindo Pharma Limited
- Dr. Reddy’s Laboratories Limited
- Lupin Limited
- Hetero Drugs Limited
- Zydus Lifesciences Limited
